Table 1.
Clinical applications and side effects of antibody-based immunotherapeutic strategies.
Strategies | Types | Clinical applications | Side effects |
---|---|---|---|
Cancer vaccines | DCs | MM, CLL | More frequently systemic flu-like symptoms occurred: fever or painful swelling of the injected lymph node |
| |||
OV therapies | MV | Leukemia, Burkitt lymphoma, HL, MM | Pneumonia, laryngotracheobronchitis, encephalitis, occasionally leading to death |
RV | MM, Burkitt lymphoma, AML, CLL | Viremia | |
VSV | MM, AML, T cell lymphoma | Neurotoxicity | |
CV | MM | No serious side effects | |
| |||
mAbs | Rituximab | Low-grade NHL, CD20+ follicular lymphoma, CLL | Fatigue, neutropenia, back pain |
Ofatumumab | R/R CLL | Infections, cough, diarrhea, anemia, fatigue, fever, neutropenia, dyspnea, nausea, rash | |
BV | HL, sALCL | Peripheral sensory neuropathy, neutropenia, fatigue, nausea, diarrhea, fever, upper respiratory infection, vomiting | |
Daratumumab | MM | Nasal congestion, cough, allergic rhinitis, throat irritation, dyspnea | |
Denileukin diftitox | CTCL | Asthenia, fever, nausea, mild hypotension, flu-like symptoms, myalgias, chills, vomiting | |
Nivolumab | HL | Fatigue, infusion reaction, arthralgia, rash | |
Pembrolizumab | HL | Pneumonitis, nephrotic syndrome | |
| |||
CAR-T cell therapies | CAR-T19 | ALL, DLBCL, B-NHL, CLL | CRS, neurotoxicity, B cell lacking |
CAR-T-BCMA | MM | CRS, neurotoxicity |